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Purpose: The standard treatment for secondary aortoenteric fistula (SAEF) has been 
infected graft removal (IGR) and extraanatomic bypass (EAB), an approach criticized for 
its high rate of death, amputation, and disruption of aortic closure. Recently, graft excision 
and in situ graft replacement has been proposed as a safer treatment alternative. Because 
the current outcome that can be achieved by use of the standard treatment of SAEF has 
really not been established, we reviewed the records of 33 patients treated for SAEF at our 
institution during a contemporary time interval (1980 to 1992). 
Methods: Thirteen patients (39.4%) were admitted with evidence of gastrointestinal 
bleeding and infection, whereas nine (27.3%) only had bleeding, 10 (30.3%) only had 
signs of infection, and one SAEF was entirely occult (graft thrombosis). Four patients 
required emergency operation. Thefistula type was anastomotic in 13 (39.4%) patients, 
paraprosthetic in 15 (45.5%), and not specified in 4 cases. Thirty-two patients underwent 
EAB followed immediately by IGR (n = 16, 48.5%) or followed by IGR after a short 
interval, averaging 3.9days (n = 16, 48.5%). The final patient underwent IGR, followed 
by EAB. 
Results: Follow-up on 31 patients (93.9%) averaged 4.4 - 3.7 years. There were nine 
deaths (27.3%) resulting from the SAEF, six perioperative and three late. Three patients 
(9.1%) had disrupted aortic closure. There were four amputations in three patients 
(9.1%), two perioperative and two late. Late EAB infection occurred in five patients 
(15.2%), leading to one death and one amputation. EAB failure occurred in six patients, 
two during operation and four late, leading to one amputation. The cumulative cure rate 
for this SAEF group was 70% at 3 years and thereafter. Compared with our earlier SAEF 
experience, this is a decline of 21% in the mortality rate, 19% in aortic disruption, and 27% 
in limb loss. 
Conclusions: We conclude that outcome reports based on SAEF series extending over long 
time intervals do not accurately represent the results that are currently achieved with 
standard SAEF treatment with use of EAB plus IGR. This improved outcome isattributed 
to wide debridement ofinfected tissue beds, reduced intervals of lower body ischemia, and 
advances in perioperative management. To determine whether any new treatment 
approach actually offers improved outcome in the management of SAEF, comparison with 
EAB plus IGR should be limited to patients treated within the last decade at most. (J VASC 
SURG 1995;21:184-96.) 
Secondary aortoenteric fistula (SAEF) remains a 
devastating complication of aortic prosthetic graft- 
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ing, with an observed incidence between 0.36% and 
1.6%. 19 The treatment of SAEF, by use of a variety 
of operative approaches, a  a reported mortality rate 
between 25% and 90%, 4'6"3° an associated major 
amputation rate varying from 5% to 25%, 715 and an 
aortic stump disruption rate of 10% to 50%. 2 The 
frequency of  these adverse outcomes has prompted 
some to recommend in situ aortic graft replacement 
as a safer and more successful treatment 3336 than the 
more traditional operative management, which con- 
*References 3, 5-13, 19-29, 31, 32. 
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Table I. Details of initial aortic 
graft operation 
No. % 
Indication 
Aneurysmal disease 15 45.5 
Occlusive disease 17 51.5 
Both 1 3.0 
Graft location 
Aortic tube 3 9.1 
Aortoiliac 13 39.4 
Aortofemoral 17 51.5 
Proximal anastomosis 
End-to-side 11 33.3 
End-to-end 22 66.7 
sists of infected graft removal (IGR) and extraana- 
tomic bypass (EAB). However, the outcome data 
summarized above come from series consisting of 
small numbers of patients accumulated over long 
time intervals and usually include a variety of 
operative techniques. Thus few data clearly establish 
the contemporary results that can be achieved with 
the standard treatment of IGR and EAB. To inves- 
tigate this, we reviewed the outcome of a consecutive 
series of patients with secondary aortoenteric fistula 
treated by use of EAB and infected graft excision at 
the University of California, San Francisco (UCSF) 
since 1980. 
METHODS 
Between 1980 and 1992, 47 patients with a 
diagnosis of SAEF were seen at our institution~ 
including all aortoenteric fistulas and graft-enteric 
erosions. Fourteen patients did not undergo standard 
therapy (n = 9), were referred to UCSF after treat- 
ment had been initiated elsewhere (n = 4), or had 
essentially exsanguinated before operation pro- 
gressed beyond placement of the aortic cross-clamp 
(n = 1). These patients (of whom eight survived and 
six died) were excluded from further analysis. The 
remaining 33 patients, 21 men and 12 women (mean 
age of 69.5 + 8.3 years), form the basis of this 
report. Two patients (6.1%) had their initial aortic 
graft placed at UCSF; the remaining patients 
(93.9%) underwent the initial aortic graft operation 
elsewhere. Data were obtained by review of the 
hospital charts, office records, and referring physician 
records. Follow-up was determined by record review, 
as well as by telephone interview of the patient, the 
referring physician or the current primary care 
physician. Cumulative cure rates, graft patency rates, 
and amputation rates were calculated by use of 
life-table analysis. 
Table II. Presenting symptoms and 
findings for aortoenteric fistulas 
No. % 
Bleeding presentation 
GI bleeding 22 66.7 
Only 9 27.3 
With infection 13 39.4 
None 11 33.3 
Pattern 
Acute 16 48.5 
Chronic 5 15.2 
Occult 2 6.1 
Acute and chronic 1 3.0 
Recurrent 7 21.2 
Hypotension 8 24.2 
Infection presentation 
Groin wound changes ~ 8 24.2 
Sinus tract 5 15.2 
Fever/chills 20 60.6 
Septic emboli 9 27.3 
Hypotension 3 9,1 
Pyrexia 22 66.7 
Leukocytosis 20 60.6 
Positive cultures 18 7'8.3 
Blood (n = 15) 11 73.3 
ground (n = 8) 7 87.5 
Miscellaneous presentation 
Weight loss 5 15.2 
Malaise 12 36.4 
Lower extremity ischemia 6 18.2 
Graft occlusion 7 21.2 
Pulsatile mass 6 t8.2 
G/, Gastrointestinal. 
~Erythema, swelling, pain, drainage, or bleeding. 
CLINICAL MATERIAL 
Initial aortic grafting was prompted by aneurys- 
real and occlusive disease with equal frequency (Table 
I). About half of the aortic grafts were aortofemoral 
in location and tube grafts were rare. End-to-end 
proximal anastomoses were twice as common as 
end-to-side anastomoses. 
Factors that may have contributed to the devel- 
opment of graft infection and fistula formation were 
present in 22 cases (66.7%). Six patients (18.296) had 
emergency aortic reconstruction for ruptured aneu- 
rysrns, 14 patients (42.4%) had subsequent reopera- 
tions on the aortic graft (ranging from one to three 
procedures), and nine patients (27.3%) had various 
perioperative complications, including ureteral injury 
(n = 2), duodenal injury (n = 1), concomitant gas- 
trointestinal procedure (cholecystectomy, 1; small 
bowel resection with appendectomy, 1), infection 
(pneumonia, 1; wound serornas with fever, 1; 
gram-negative s psis caused by acalculous cholecys- 
tiffs, 1) and reoperation for bleeding (n = 1). 
Most patients were admitted with some evidence 
of gastrointestinal bleeding (n = 22, 69.7%), either 
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Table III. Methods of diagnostic evaluation 
Abnormal Diagnostic 
No. No, % No. % 
Esophagogastroduodenoscopy 17 9 52.9 2 
Abdominal/pelvic CT 24 22 91.7 8 
Angiography 30 12 40.0 0 
Sinography 3 3 100.0 0 
Colonoscopy 10 6 60.0 0 
Upper GI series 8 5 62.5 1 
Lower GI series 5 2 40.0 0 
Magnetic resonance scan 6 6 100.0 0 
Gallium scan 2 1 50.0 0 
Indium WBC scan 7 4 57.1 0 
Technetium WBC scan ]_ 0 0.0 0 
11.8 
33.3 
12.5 
GI, Gastrointestinal; WBC, white blood cell. 
alone (n = 9, 24.2%) or in combination with 
symptoms and signs of infection (n = 13, 45.5%). 
However, nine patients (27.3%) showed evidence 
only of infection, without any bleeding episodes or 
even guaiac-positive stool. One aortoenteric fistula 
was entirely occult and presented as graft thrombosis. 
Most patients who bled were admitted with acute 
gastrointestinal hemorrhage, and almost one third 
had recurrent bleeding episodes before diagnosis and 
definitive therapy (Table II). However, almost all 
patients topped bleeding and were stabilized hemo- 
dynamically, such that emergency operation was only 
required four times. 
The symptoms and signs of infection were varied 
(Table II). The most frequently present were elevated 
temperature (mean Tin= = 38.2 + 0.9) and leuko- 
cytosis (13.7 _+ 5.2 109 cells/L). Preoperative cul- 
tures of wounds, drainage, or blood were only 
sporadically obtained, but they were usually positive 
(18 of 23, 78.3%). Most patients (75%) had no local 
wound changes to suggest any underlying graft 
problem. Infection alone rarely produced hypoten- 
sion (9%), whereas bleeding did more often (24%). 
Surprisingly, septic embolization occurred in more 
than one quarter of the patients in this series (Table 
II). Lower extremity ischemic symptoms were also 
present in six patients, and seven grafts were partially 
(one limb) or completely occluded. The six palpable 
pulsati!e masses were equally distributed between the 
proximal and distal anastomotic sites. Eight patients 
(24.2%) had an entirely normal physical examination 
result. 
The most common preoperative assessment con- 
sisted of esophagogastroduodenoscopy (EGD), 
computed tomography (CT) of the abdomen and 
pelvis and angiography (Table III). The resuk of 
EGD was abnormal more than half of the time, but 
it was diagnostic of SAEF in only two cases (graft 
material seen). The false-negative rate was quite high 
(47.1%). Endoscopy to the fourth portion of the 
duodenum was only documented in six patients who 
underwent EGD in this series. The CT scanning 
result was almost always abnormal, but it was 
considered to be diagnostic of aortoenteric fistula (air 
around the graft) in only eight cases. Of the 12 
arteriographic studies that showed abnormalities 
suggesting possible graft infection, four showed 
proximal suture line (aortic) false aneurysms, six 
showed distal suture line (femoral or iliac) false 
aneurysms, one study showed proximal and distal 
suture line false aneurysms, and one study showed 
intraluminal graft limb filling defects. Although these 
findings were consistent with a graft infection, they 
were only suggestive of SAEF. Consequently, the 
diagnosis of SAEF was definitively made before 
operation in only 11 patients (33.3%). It was 
suspected and confirmed uring operation in 17 cases 
(51.5%), and it was unsuspected until encountered 
during operation in the remaining five patients 
(15.2%). A variety of other investigative modalities 
were used less commonly in this patient group, but 
were only responsible for one additional confirmed 
preoperative diagnosis (Table III). For the most part 
these tests demonstrated findings diagnostic of or 
strongly suggestive of a graft infection but did not 
offer definitive vidence for the presence of a fistula. 
The mean interval between placement of the 
original aortic graft and definitive treatment ofSAEF 
by graft excision and EAB was 6.1 --- 4.1 years. For 
those patients who underwent reoperation on the 
aortic graft at some point, the mean interval between 
the most recent operation and the graft removal was 
4.3 +__ 3.8 years. The typical elapsed time between 
the onset of symptoms and definitive operative 
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Table IV. Details of graft 
infection operation 
No. % 
Type 
Emergency 4 12.1 
Urgent 29 87.9 
Technique 
Sequential 16 48.5 
Staged 16 48.5 
Traditional 1 3.0 
Axillofemoral bypass 
outflow artery 
Common femoral 14 42.4 
Superficial femoral 12 36.4 
Deep femoral 5 15.2 
Small graft remnant 2 6.1 
Cross-femoral conduit 
Prosthetic 13 39.4 
Saphenous vein 11 33.3 
Ilioiliac anastomosis 5 15.2 
Endarterectomized su- 2 6.1 
perficial femoral artery 
Combination 2 6.1 
Infected graft removal 
Complete 28 84.8 
Complete (intention to 3 9.1 
treat) 
Partial 2 6.1 
Aortic clamp level 
Supraceliac 4 12.1 
Suprarenal 10 30.3 
Infrarenal 17 51.5 
Other 2 6.1 
Aortic stump protection 
None 21 63.6 
Omenmm 3 9.1 
Anterior spinal igament 2 6.1 
Unknown 1 3.0 
Not applicable 6 18.2 
treatment was 84.8 + 91.8 days. In spite of this 
diagnostic delay, only four emergency operations 
(12.1%) were necessary. 
Thirty-two patients underwent EAB first, fol- 
lowed by infected graft removal and fistula closure, 
either under the same anesthesia (sequential tech- 
nique, n = 16, 48.5%) or after a brief interval 
(staged technique, n = 16, 48.5%). The average 
staging interval was 3.9 _+ 2.3 days (range 1 to 8 
days, median 4 days). Two patients who were to 
undergo staged graft removal died before the second 
stage could be performed, one of aortic false aneu- 
rysm rupture and one of the consequences of 
prolonged lower body ischemia. The final patient 
underwent aortic graft removal and fistula closure 
first, followed immediately by EAB (traditional 
technique). 
Infected graft removal was complete in 28 pa- 
tients (84.8%). Two of the remaining five patients arc 
Table V. Details of aortoenteric fistulas 
No. % 
Type 
Anastomotic 13 39.4 
Paraprosthetic 15 45.5 
Both i 3.0 
Unknown 4 12.1 
Location 
Duodenum 23 69.7 
Jejunum 6 18.2 
Both 1 3,0 
Ileum 2 6.1 
Sigmoid colon 1 3.0 
described above and are included in the complete 
excision group on the basis of intention to treat. In 
one additional patient a small remnant of graft was 
inadvertently left in the right groin and is also 
considered to be in the complete xcision group. The 
two remaining patients (6.1%) each had small cuffs 
of the old graft intentionally left in place at the 
femoral anastomotic sites. Infected graft removal 
occasionally required supracehac (u = 4) or supra- 
renal (n = 10) aortic clamping but was performed 
with infrarenal aortic clamping in the remainder of 
the cases (Table IV). Methods to protect he aortic 
stump were rarely used, but aggressive excision and 
debridement of the retroperitoneum and the aorta 
were always performed, and a tension-free, two-layer 
aortic closure with monofilament suture was stan- 
dard. The retroperitoneum is not routinely drained, 
but drains are more likely to be placed if there is a 
large, defined abscess cavity. 
The extraanatomic revascularization consisted of 
an axillofemoral bypass to either the ipsilateral 
common femoral, superficial femoral, or deep femo- 
ral arte U (Table IV). The large number of" intraab- 
dominal grafts in this series allowed manly of the 
distal anastomoses of the axillofemoral graft to be 
performed to the common femoral artew, because 
there was no prosthetic material in the groins in 49% 
of the cases. Similarly this allowed the femorofemoral 
conduit o be prosthetic (n = 13) or to be fashioned 
by end-to-end anastomosis of the common lilac 
arteries (n = 5) in more than half of the cases (Table 
iv). 
The aortoenteric fistulas were equally divided 
between anastomofic mad paraprosthetic (Table V). 
Almost all fistulas were located in either the duode- 
num or proximal jejunum (87.9%), but they occa- 
sionally involved the colon or distal small bowel. 
Preoperative wound or wound drainage cultures 
were almost always positive for multiple organisms 
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Table VI. Culture results 
Single organism Multiple organisms S. Epidermidis Only S. epidermidis 
No. No. % No. % No. % No. % 
Preoperative 
Wound/drainage 8 0 - 7 87.5 1 12.5 0 - 
Blood 15 4 26.7 6 40.0 0 - 0 - 
Intraoperative 
Graft 2I 6 28.6 8 38.1 0 - 0 - 
Perigraft issue 30 8 26.7 14 46.7 3 I0.0 1 3.3 
Artery 9 4 44.4 2 22.2 0 - 0 - 
Miscellaneous sites ~ 7 2 28.6 3 42.9 0 - 0 - 
~Buttock/foot/knee abscesses; thrombus; retroperitoneum. 
Table VII. Outcome of treatment for aortoenteric fistulas 
Perioperative Late Total 
No. % No. % No. % 
Death 6 18.2 3 9.1 9 27.2 
Amputation 2 6.1 1 3.0 3 9.1 
Aortic stump disruption 2 6.1 1 3.0 3 9.1 
EAB occlusion 2 6.1 4 12.1 6 18.2 
EAB infection 0 - 5 15.2 5 15.2 
(Table VI), as were preoperative blood cultures. 
Intraoperative graft and perigraft tissue cultures 
usually grew multiple organisms, whereas intraop- 
erative artery cultures were more likely to grow a 
single organism. Overall single-organism isolates 
were somewhat less common than multiple isolates 
(26.7% vs 44.4%). Staphylococcus epidermidis was 
isolated from four cases. In one case it was the solitary 
organism recovered from the graft/perigraft tissue, 
but Pseudomonas was also cultured from the aortic 
wall. However, no special techniques were used to 
increase the recovery rate for S. epidermidis. There 
were only four entirely culture-negative infections 
among this patient group. 
RESULTS 
Mortality. There were six perioperative (< 30 
days) deaths (18.2%). Two patients who were 
expected to have staged treatment oftheir aortic graft 
infection died between the first- and second-stage 
operations. In one case the proximal aortic false 
aneurysm ruptured 2days after EAB, and the patient 
could not be saved by emergency operation. The 
second patient was admitted with extensive pelvic 
and lower body ischemia caused by thrombosis of her 
aortofemoral graft. Even after EAB these changes 
were irreversible, and thus the second-stage proce- 
dure was never performed. One patient had a 
respiratory arrest of unknown cause, and autopsy was 
not performed. One patient died of sepsis of unde- 
termined cause, but it was presumed to represent 
persistent retroperitoneal infection. One patient died 
of metastatic pancreatic carcinoma, which was found 
incidentally at the time of infected graft removal. In 
the final patient her aortic closure ruptured 10 days 
after IGR, and autopsy revealed fungal aortitis. Of 
note this patient did not have an interrupted and 
oversewn aorta (aortic stump) but had primary 
closure of the longitudinal aortic defect created by 
removing the end-to-side aortic graft. 
There were three late deaths related to the aortic 
graft infection (9.1%). Two patients died of aortic 
stump disruption, one at 2.3 months and one at 5.1 
months after operation. Of note, in the latter patient 
the aortic stump first disrupted perioperatively, and 
he survived emergency repair. In total there were four 
instances of aortic stump disruption in three patients 
(9.1%), ultimately causing death in all three of the 
patients. The final death occurred in a patient who 
underwent redo in-line aortic reconstruction because 
of infection involving the prosthetic axillofemoral 
graft. Unfommately she had development of a 
second aortoenteric fistula (not to the duodenum, as 
in her original fistula, but to the sigmoid colon), and 
she ultimately died as a result of that complication. 
The crude overall mortality rate for this series is 
27.2% (Table VII). During follow-up, which aver- 
aged 4.4 + 3.7 years, life-table analysis shows the 
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Fig. 1. Life-table shows cumulative rate of cure for aortoenteric fistula and graft infection 
managed by EAB followed by IGR and fistula closure. Maximum SE = 8.7%. 
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Fig. 2. Life-table shows cumulative primary and secondary patency rates of extraanatomic 
revascularizations used in this series ofpatients. Maximum SE = 10.8% for primary patency and 
7.0% for secondary patency. 
cumulative cure rate for the treatment of the aor- 
toenteric fistula and graft infection was 74.5% at 1 
year, reached 70% at 3 years, and remained constant 
thereafter (Fig. 1). 
Extraanatomic bypass failure. There were six 
failures of the extraanatomic bypass, two periopera- 
tively and four during follow-up, for a crude inci- 
dence of 18.2% (Table VII). One patient with a 
perioperative EAB thrombosis had a successful 
thrombectomy but required one above-the-knee 
amputation and was then lost to follow-up. Three 
failed grafts underwent successful thrombectomy 
with or without graft revision and thereafter re- 
mained patent throughout follow-up. Two grafts 
remained chronically occluded and necessitated re- 
placement with a contralateral EAB. Altogether the 
six patients required 13 operations to correct hese 
failures of the EAB. The primary and secondary 
patency rates for these extraanatomic reconstructions 
are summarized in Fig. 2. By life-table analysis the 
1-year primary patency rate was 84.3%, whereas the 
secondary patency rate was 95.4%. At 4 years the 
primary patency rate was 71.0%, and the secondary 
patency rate was 89.6%. Thereafter there were no 
further graft failures. 
Limb salvage. Three patients required four 
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cumulative limb salvage during follow-up. Maximum 
major limb amputations (two above-knee, two 
below-knee), a crude incidence of 9.1%. Two am- 
putations resulted from the treatment of infected 
EABs. One resulted from EAB thrombosis. The 
cumulative limb salvage is summarized in Fig. 3. 
EAB infection. Five patients had development 
of infection of the prosthetic axillofemoral bypass 
during follow-up. Three were successfully treated by 
placement of a new contralateral xillofemoral graft 
and excision of the infected conduit. Two EAB 
infections resulted in amputation and death in one 
patient, and amputation alone in the other patient. 
Altogether the five patients underwent 10 operations 
for treatment of the EAB infection. 
DISCUSSION 
The controversy over the optimal method of 
treatment for secondary aortoenteric fistula has been 
fueled by continued publication of series showing 
high mortality, amputation, and aortic stump dis- 
ruption rates. In 1983 Bunt  29 summarized the 
reported experience in the management of SAEF. 
Excluding patients whose operative management 
consisted of laparotomy only, the overall mortality 
rate was 58.4%. For the most part, this represented 
the perioperative mortality rate because the series did 
not contain information regarding late mortality 
rates. Furthermore, data regarding the incidence of 
amputation or disruption of the aortic stump were 
not included in that review. Three years earlier, 
Kiernan et al. had reported a less exhaustive r view of 
published cases and noted a similar mortality rate of 
52.8%, with a perioperative rate of 46.5% and a late 
death rate of 6.3%. His report also contained no data 
regarding the frequency of amputation but did note 
aortic stump disruption in 10.3% of cases. In the 
series published since Bunt's review 29 (or not in- 
cluded in his review), which include data specific 
to the outcome of treatment of aortoenteric fistu- 
las, 4,628,3°,33-36 the overall mortality rate remains 
57.0%. Only one third of these series 7-15 include am- 
putation data, which occurred on average in 8.8% of 
cases. However, most of the studies did report aortic 
stump disruption rates, which averaged 21.6%.t 
In analyzing these outcomes, it is evident that the 
data generally are based on small-volume studies, 
which accumulated patients over very long time 
intervals. In spite of the fact that several series have 
reported improved results in more recently treated 
patients with SAEF 6,15,2s or aortic graft infection in 
general, 3 3° the effect of including all patients treated 
over long time intervals has not really been consid- 
ered when comparison is made between operative 
approaches. Furthermore in these reports avariety of 
operative techniques are used, including local repair, 
graft excision without revascularization, graft exci- 
sion with in situ replacement, and graft excision with 
EAB. Thus pooling this data cannot provide clear 
information regarding the current outcome, which 
can be achieved with one consistent reatment 
approach. 
The results reported in our contemporary series of 
patients with SAEF represent a 21% reduction in 
mortality rate, a 27% reduction in limb loss, and a 
~Rcfercnccs 3, 5-13, 19-29, 31, 32. 
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Table VI I I .  Results of graft removal and extraanatomic bypass for aortoenteric fistula 
Mortality 
Stud), interval Follow-up Stump 
Stud), Study dates (yr) No. Perioperative Late Total period d#ruption 
Selected series 
Kiernan et al. 23 1964-1978 14 6 3 (50.0%) 1 (16.7%) 4 (66.7%) NS 2 (33.3%) 
Shah et al, 28 NS 2 3 1 (33.3%) 1 (33.3%) 2 (66,7%) 2.0 0 
Flye et al. 2° 1970-1982 12 10 NS NS 7 (70.0%) NS 0 
Gozzetti et  at. 22 1960-1982 22 1 0 0 0 2.0 0 
Trout et al. la NS NS 4 1 (25.0%) 0 1 (25.0%) 3.5 0 
Yeager et al. is 1975-1984 9 7 3 (42.9%) 0 3 (42.9%) 1.3 0 
Thomas et al. a4 NS 4 1 ! (100%) 0 1 (100%) 0.1 0 
Salo et al. TM 1974-1984 10 9 4 (44.4%) 1 (11.1%) 5 (55.6%) NS NS 
Moulton et al. 24 1978-1985 7 13 4 (30.8%) 3 (23.1%) 7 (53.9%) NS 5 (38.5%) 
Vollmar et aL 3s 1974-1984 10 6 NS NS 5 (83.3%) NS NS 
Umpleby et al. ~4 1980-1984 4 7 1 (14.3%) 2 (28.6%) 3 (42.9%) 0.6 1 (14.3%) 
Tilanus et al. 19 1978-1985 7 10 7 (70.0%) NS 7 (70.0%) NS 3 (30.0%) 
Aarnio et al. l° 1985-1988 3 3 0 1 (33.3%) 1 (33.3%) 1.0 0 
Higgins et aL 8 1977-1987 10 7 2 (28.6%) 2 (28.6%) 4 (57.1%) 0.5 I (14.3%) 
Jacobs et  al .  I6 1972-1989 17 2 0 0 0 4.5 0 
Bergeron et al. 6 1970-1989 19 17 4 (23.5%) 3 (17.6%) 7 (41.2%) 4.0 5 (29.4%) 
Bacourt 41 1979-1989 10 40 12 (30.0%) NS 12 (30.0%) NS 6 (i5.0%) 
Peck et al. 9 1980-1991 11 21 __ NS __ NS 1_! (52.4%) NS 3 (12.0%) 
Average 10.1 9.3 43 (33.1%) 14 (17.5%) 80 (47.9%) 26 (17.1%) 
Literature review (25 series) 
Bunt 29 1952-1982 30 93 NS NS 34 (36.4%) NS NS 
NS, Not clearly stated. 
19% reduction in the rate of aortic stump disruption 
when compared with the results we obtained among 
patients treated uring the preceding 15 years. 37 We 
believe the improved survival rate may result from a 
number factors. First, of  course, is the dramatic and 
ongoing improvement in preoperative preparation, 
intraoperative anesthetic management, and postop- 
erative care that has occurred in the past quarter 
century. Second, the importance of thorough de- 
bridement of the infected retroperitoneum and 
perigraft issue and of  the infected artery (aorta) in 
the successful management of these patients has 
gradually become apparent. At the time of infected 
graft removal we routinely debride all necrotic and 
obviously infected retroperitoneal tissue, while pre- 
serving necessary vital structures. This debridement 
includes any false aneurysm wall, abscess cavity, 
perigraft capsule (including that extending along the 
graft limbs), the necrotic margins of the bowel wall 
at the fistula site, and, finally, the involved aorta itself. 
It  is mandatory to close the aorta at a level where it 
appears healthy and not involved by infection. 
Attempts to close obviously infected aorta will fail, 
and this will probably be fatal. Frequent use of  
suprarenal or supravisceral ortic cross-clamping will 
allow more proximal aortic debridement. It  is almost 
always possible to close the aorta below the renal 
arteries and still be above the level of  aortic wall 
involvement. However, if the aorta is involved at the 
renal artery level, then renal revascularization with 
the splenorenal or hepatorenal technique isnecessary. 
In this series no patient required renal artery reloca- 
tion to allow more proximal closure of the aortic 
stump. 
Finally, routine performance ofthe extraanatomic 
revascularization before the transabdominal removal 
of the infected graft has allowed us to avoid lower 
body ischemia with all of  its adverse metabolic 
consequences. 38 This last factor may help to explain 
why our survival rate with EAB and IGR is better 
than the survival rates recently reported in the 
literature (Table VII I) .  O f  the 18 series summarized 
in Table VI I I ,  12 used the traditional operation 
sequence (IGRfollowed by extraanatomic revascular- 
ization) in all or most of their patients.~ Pccket al. 9 
did report a 25% mortality rate in patients treated by 
EAB followed by IGR, in comparison to a 64% 
mortality rate for those who underwent he tradi- 
tional sequence of operations. Those authors were 
quick to point out that this difference in survival 
results, at least in part, from the greater frequency of  
hemodynamic instability among patients in whom 
graft removal was required first because of bleeding. 
However, not all patients undergoing the traditional 
sequence of operations in their or other series were 
actually hemodynamically unstable. 
::References 9, 10, 14-16, 18, 19, 22, 24, 28, 34, 35. 
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Obviously not all patients are candidates for EAB 
first followed by IGR. Because the course of bleeding 
associated with an aortoenteric fistula is unpredict- 
able, the treatment technique chosen for any patient 
whose presentation has included active bleeding must 
be carefully individualized. A patient who has active 
bleeding at the time of initial presentation that has 
not stopped or stabilized is not a candidate for EAB 
followed by IGR. A patient who has had active 
bleeding,, with associated hemodynamic instability, 
but that has stopped and stabilized with appropriate 
resuscitation, is a candidate for EAB followed by IGR 
at the same operation, without an interval delay. A 
patient who has had active bleeding but without any 
instability is a candidate for EAB followed by IGR 
with or without an interval delay. However, for this 
patient any interval delay should be kept very brief, 
particularly if there is an associated proximal anasto- 
motic false aneurysm. A patient who has only had 
occult bleeding clearly is a candidate for EAB before 
IGR, and the staged approach is appropriate. Again 
if there is an associated aortic false aneurysm, the 
staging interval should be minimal. The length of the 
staging interval is entirely empiric and in general 
should be as short as the patient's condition will 
allow. Over time we have progressively shortened 
this interval. 
In addition to the bleeding pattern, the decision 
to perform both parts of the procedure with the 
patient under the same anesthesia s also influenced 
by the expected length of each part of the procedure. 
When the EAB will be short and straightforward (as 
is the case when the infected aortic graft is a tube graft 
or an aortoiliac graft, thereby allowing a prosthetic 
cross-femoral graft to be placed in previously non- 
operated groins), we are more likely to complete the 
procedure at one setting. When the EAB portion of 
the procedure is expected to be lengthy (as occurs 
when the infected aortic graft extends into the groins 
and autogenous repair in previously operated fields is 
necessary), we are more likely to use the staged 
approach. 
Eliminating extended periods of extensive lower 
body ischemia lso contributes to the lower rate of 
major limb loss reported in this series. Equally 
important in preventing limb loss is our routine use 
of axillofemoral/femorofemoral bypass, which pro- 
vides bilateral lower extremity revascularization. Fur- 
thermore, retrograde flow into the pelvis is also 
maintained. This combination results in the maximal 
outflow for an EAB, which correlates with increased 
long-term patency. Although it is often difficult to 
determine exactly the technique of EAB performed in
other published series, unilateral xillofemoral bypass 
to each leg is not uncommonly used, 6,8,28 and its 
expected lower patency rates would increase the risk 
of major amputation. Finally in our group of patients 
cross-femoral flow could more often (54.5%) be 
established with prosthetic material or direct ilioiliac 
anastomosis because of the higher incidence of 
underlying aneurysmal disease and the consequent 
lesser incidence of infected aortofemoral grafts. The 
ability to use a prosthetic or ilioiliac conduit elimi- 
nates the influence of conduit size on patency. As 
Clagett et al. 39 have recently reported, autogenous 
cross-femoral grafts are more likely to fail when the 
caliber of the conduit is suboptimal. We have had this 
same experience in our total series of infected aortic 
grafts, in which the cross-femoral conduit failure was 
0% for prosthetic conduits, 10% for ilioiliac anasto- 
mosis, 15.8% for vein conduits, and 26.7% when 
endarterectomized superficial femoral artery was 
used. 
Because almost all of the patients in this series 
initially presented elsewhere and were referred to 
UCSF for treatment ofthe SAEF, it is almost certain 
that these patients represent a selected group who 
were hemodynamically stable enough to tolerate the 
delay associated with transfer from another institu- 
tion. By definition this means that the more hemo- 
dynamically unstable patients at higher isk were not 
included. This would increase the likelihood that we 
could successfully perform our preferred technique of 
revascularization before infected graft removal and 
would also tend to improve overall survival. 
It seems clear that consistent use of EAB followed 
by infected graft removal can currently produce 
substantially better outcomes than could previously 
be achieved in the management of secondary aor- 
toenteric fistula. It is against this yardstick that 
alternative treatment approaches must be measured. 
The published experience ofin situ graft replacement 
for SAEF consists mostly of small series, with a few 
cases treated in this manner among a larger group of 
patients with SAEF treated with a variety other 
techniques (Table IX). Only two studies used in situ 
graft replacement exclusively32,36; in three additional 
reports in situ graft replacement accounted for half or 
more of the treated patients. 16,22,3s Only one study 
contained more than 10 patients. 36 In that series of 23 
patients, there were five early deaths- including two 
from persistent sepsis and one from persistent sepsis 
with recurrent fistula- and there were two late deaths 
caused by rupture of a false aneurysm atthe proximal 
anastomosis, for an overall mortality rate of 30.4%. 
An additional patient required reoperation to repair 
JOURNAL OF VASCULAR SURGERY 
Volume 21, Number 2 Kuestner et aI, 193 
Table IX. Results of in situ graft replacement for aortoenteric fistula 
Study Stuffy gates 
Study Mortality 
interval 
(yr) No. Perioperative Late Total 
Follow-up Stump Reinfection 
period disruption rate 
Selected series 
Kiernan et al. 23 1964-1978 14 7 3 (42.9%) 1 (14.3%) 4 (57.1%) 
Flye et al. 2° 1970-1982 12 3 NS NS 1 (33.3%) 
Gozzetti et al. = 1960-1982 22 4 2 (50.0%) 0 2 (50.0%) 
O'Hara et al? 1961-1985 24 6 5 (83.3%) 0 5 (83.3%) 
Thomas et al? 4 NS 4 2 0 0 0 
Salo et al. 18 1974-1984 10 1 0 0 0 
Moulton et al. 24 1978-1985 7 2 0 1 (50.0%) 1 (50.0%) 
Walker et al. a6 1972-1985 13 23 4 (17.4%) 3 (13.0%) 7 (30.4%) 
Vollmar et al? 5 1974-1984 10 7 NS NS 1 (I4.3%) 
Umpleby et a154 1980-1984 4 1 0 1 (100%) 1 (I00%) 
8orenson et alY NS NS 1 0 0 0 
Higgins et al. 8 1977-1987 10 4 0 1 (25.0%) 1 (25.0%) 
Jacobs et al) 6 1972-1989 17 7 4 (57.I%) 0 4 (57.1%) 
Robinson et al. a3 1978-1989 11 4 0 0 0 
Bergeron et al. 6 1970-1989 19 1 _!1 (100%) _0 1 (100%) 
Average 12.6 4.9 19 (30.2%) 7 (11.1%) 28 (38.4%) 
Literature review (28 series) 
Bunt  29 1952-1982 30 70 NS NS 41 (58.6%) 
Ns ~ (14.3%) o 
NS NS NS 
2.8 2 (50,0%) NS 
NS NS NS 
3.3 0 0 
3.0 NS NS 
NS 1 (50.0%) NS 
5.2 4 (17.4%) 2 (8.7%) 
NS NS NS 
2.0 1 (100%) YS 
NS 1 (100%) NS 
NS 2 (50.0%) 0 
4.3 NS 1 (14.3%) 
4,0 0 0 
NS ~ _0 
12 (24.5%) 3 (6.3%) 
NS NS NS 
NS, Not clearly stated. 
a large proximal anastomotic false aneurysm. Two 
patients were lost to follow-up. Therefore the overall 
rate of cure or successful treatment was 56.5%. On 
average all of these studies contained 4.8 patients 
each, accumulated over an average interval of 13 years 
(Table IX). 'The consistent low volume experience 
with this technique makes it impossible to eliminate 
the serious potential for sampling error when inter- 
preting the results. To the overall mortality rate of 
38% one must also add the additional treatment 
failures resulting from false aneurysm formation or 
reinfection of the newly placed graft, sometimes 
resulting in late death and sometimes requiring 
reoperation with ultimate resection of the in situ graft 
and placement of an EAB. In many of the published 
series this information is not available. When it can be 
determined it results in an overall success rate that 
approaches the results in Walker's eries. 
Finally, it is interesting to note that in situ graft 
replacement does have an associated incidence of 
disruption of the proximal aortic suture line that is 
somewhat greater than the frequency of aortic stump 
disruption in those patients who have graft removal 
and oversewing of the aorta (Tables VIII and IX). It 
is possible that in-line graft replacement may result in 
less extensive debridement of the aorta, which may 
allow persistent infection to remain in the aortic wall, 
leading to false aneurysm formation, with or without 
recurrent fisnflization or rupture. Clearly, then, 
maintaining aortic continuity by replacing the graft 
does not eliminate the possibility of aortic disruption, 
as has been suggested by some authors. ~6,34,36 
An additional factor that is believed to influence 
the outcome after treatment of aortic graft infection 
is the nature of the infecting organism. In our study 
group 20 patients had gram-negative organisms 
recovered from culture of the graft or perigraft tissue, 
whereas an additional five patients had gram-negative 
organisms cultured from wound or blood, an overall 
frequency of gram-negative infection of 75.8%: 
Because only four cases were entirely culture nega- 
tive, the cure rate in this series is not likely due to a 
higher frequency of low-virtflence infecting organ- 
isms. Furthermore, this distribution of infecting 
organisms underscores the fact that in situ graft 
replacement for SAEF can rarely be justified by the 
experimental data, suggesting some success with in 
situ replacement for coagulase-negative graft infec- 
tions. 4° 
This series establishes the outcome that can be 
achieved currently with the standard approach of 
EAB followed by infected graft removal in the 
treatment of secondary aortoenteric fistula. The 
improved results noted in this recent experience are 
attributed to improved perioperative management; 
elimination of extended periods of lower body 
ischemia by routine performance of the revascular- 
ization first; routine use of axillobifemoral bypass 
with preservation fretrograde pelvic flow to provide 
optimal EAB run-off and thus increase patency; and 
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routine aggressive debridement of involved artery, 
perigraft tissue, and retroperitoneum to reduce the 
risk of persistent retroperitoneal infection or aortic 
stump disruption. 
Obviously not every patient with a secondary 
aortoenteric fistula will be a candidate for this 
standard treatment. Inevitably there will be a certain 
percentage of patients diagnosed with acute hemor- 
rhage and hemodynamic instability who will need a 
different approach. However, when the clinical 
circumstances permit- and we believe this will be the 
case for the substantial majority of patients-the 
present optimal treatment for secondary aortoenteric 
fistula consists of rcvascularization first, followed by 
IGR. 
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DISCUSSION 
Dr. G. Patrick Clagett (Dallas, Texas). This study 
contains a wealth of detail that is strikingly absent from 
most retrospective studies ofaortoenteric fistula. In review- 
ing the literature, one is continually frustrated by the 
paucity of hard data that makes comparison between series 
and methods of treatment impossible. 
With regard to the authors' conclusions, I find little 
with which to disagree. In situ aortic replacement with 
prosthetic material is occasionally successful but too 
unreliable to be used except in desperate circumstances. We 
have used in situ replacement with autogenous tissue 
fashioned from deep veins and have had a gratifying, less 
than 10% mortality and amputation rate in more than 30 
patients with aortic prosthetic infections. However, in our 
subgroup of patients with aortoenteric fistula, our results 
have been less favorable, and we still prefer the standard 
approach advocated here. 
Fourteen patients were excluded from analysis. Can 
you tell us more about them? By strict intention-to-treat 
principles, they should be included in your overall experi- 
ence. What would your mortality rate have been if these 
were included? 
Your patients are obviously a referral population, and 
this is reflected in the fact that only four required 
emergency operation. In my own experience, most of these 
cases are emergencies and occur in the middle of the night. 
Don't you think that your good results are to some degree 
due to the referral pattern and selection bias in that these 
are mostly stable patients? 
I am uneasy about staging this operation if true 
aortoenteric fistula is present. I note that you had one death 
from exsanguination during the interim between EAB and 
graft removal. Would you tell us how you decide whether 
to stage the operation? 
Dr. Laurie M. Kuestner. With regard to your first 
question about he 14 patients who were excluded from the 
study, the 14 patients consisted of four patients who were 
transferred to our institution after therapy had been 
initiated elsewhere. The remaining 10 patients did not 
undergo standard therapy, and they were excluded on this 
basis. Four underwent autologous reconstructions, three 
underwent in situ graft replacement, one patient had an 
IGR alone without revascularization, another patient had 
local therapy only, and a final patient exsanguinated during 
operation without any definitive therapy other than place- 
ment of an aortic clamp. It's difficult in a retrospective study 
to determine the intention to treat. However, we included 
all patients in whom we believed the intention to treat was 
EAB and IGR. 
In reviewing our 10 patients who were excluded who 
did not undergo the standard therapy, perhaps the one 
patient who exsanguinated during operation could be 
included in our series. This changes the mortality rate from 
27% to 29%. 
Regarding the second question, I agree that the small 
number of emergency operations in this series, that is, four, 
does reflect that our population is mainly a referra! 
population. The fact that only four patients required 
emergency surgery is a consequence ofthe patient s~arviving 
to be transferred to the university. This represents a
selection bias. 
With regard to your third question, how we decide 
whether a patient undergoes staged or sequential repair, it 
has been our experience that one third of the patients have 
symptoms of infection only without gastrointestinal bleed- 
ing. In these patients, we do not hesitate to proceed with 
staged repair. In the remaining patients who do have 
gastrointestinal b eeding, about two thirds are admitted 
with acute bleeding and the other one third has chronic 
bleeding or simply guaiac-positive stool. In the latter group 
of patients with a slow chronic bleed or occult blood in the 
stool, we proceed with a staged reconstruction. In the 
patients with acute gastrointestinal bleeding, we usually 
perform a sequential technique that is EAB followed by 
IGR with the patient under the same anesthesia. 
Dr. John I. Ricotta (Buffalo, N.Y.). It appears that 
you were able to make the diagnosis of aortoenteric fistula 
before operation in all of your patients, thus allowing 
elective placement of an axillary bifemoral graft: before 
abdominal exploration. Can you tell us how you make this 
diagnosis with certainty? We have found this to be 
particularly difficult in patients diagnosed with significant 
hemorrhage. What would you suggest be done when a 
patient is admitted with hemorrhage and your preoperative 
evaluation leaves the site of bleeding in doubt? 
Dr. Kuestner. You stated that you assumed from our 
study that all of the patients were known to have an 
aortoenteric fistula before operation, and you wondered 
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how we determined this and how we treat he patient when 
the diagnosis is not clear. Most of the patients were 
evaluated with an EGD, CT scans of the abdomen, pelvis, 
and angiography. For the most part, these studies con- 
firmed a graft infection but did not confirm an aortoenteric 
fistula. All the patients in the series did not have a 
preoperative diagnosis of an aortoenteric fistula. In fact, 
only one third had a definitive diagnosis of aortoenteric 
fistula before operation. Fifty percent of the patients had a 
suspected iagnosis of aortoenteric fistula that was con- 
firmed during operation; in 15% of patients it was not 
suspected but was found during operation. 
In the patient with significant hemorrhage, we recom- 
mend a three-stage approach: first, perform an exploratory 
laparotomy to control the life-threatening hemorrhage, and 
then, once the patient's condition is stable, proceed with 
EAB followed by IGR. 
Dr. John E. Connolly (Irvine, Calif.). This study is an 
important contribution to the management of SAEF. The 
authors have shown that the mortality rate of the conven- 
tional operation for removal of the graft with EAB can be 
performed with a mortality rate half that commonly 
reported. 
I believe that these improved results can be attributed 
to several reasons. First, almost all of the authors' cases were 
nonemergencies; second, in all cases except one, the EAB 
was performed initially; third, that it was possible to 
construct he axillary bifemoral grafts into the common 
femoral arteries in most cases because the original infected 
grafts entered the external iliac arteries; and last, the 
operations were carried out by very experienced surgeons. 
What we now need is comparable long-term data on the 
alternative treatment of either in situ new graft placement 
or simple fistula closure. 
I note that half of the authors' patients had their 
original grafts placed for occlusive disease and about half of 
these were end-to-side aortobifemoral grafts. I suggest that 
an alternative to graft removal and EAB is to convert he 
operation to a standard aortoiliac endarterectomy in those 
cases where that operation was an alternative at the original 
procedure. I have done that in two cases over the past 20 
years. Both were long-term successes. The secret is to 
examine the original aortogram to determine whether the 
occlusive disease was suitable for endarterectomy. The 
aortic and femoral take-off sites are examined at surgery, 
and if patching appears to be necessary, saphenous vein or 
hypogastric artery patch material is harvested before 
clamping the filnctional bypass to minimize distal flow 
interruption at the time aortoiliac endarterectomy is 
performed. This procedure is ideal because all prosthetic 
graft is removed, and none is added by EAB. Obviously, 
end-to-end proximal aortic anastomosis precludes uch a 
procedure. 
The senior authors of this study (Ehrenfeld WK, et al. 
Surgery 1978;85:82-92) presented ata on the use of 
autogenous tissue on reconstruction in the management of 
infected grafts. Therefore I want to ask the authors whether 
they have ever used the endarterectomy technique for 
infected aortoenteric fistulas, and if not, what do they think 
of its possible use? 
Dr. Kuestner. You stated that the senior authors of  
this study had presented a report 15 years ago discussing 
the use of autologous reconstruction for infected grafting. 
During the time when this series was collected, there were 
four patients who underwent autologous reconstruction. 
The series reported by the senior authors only included two 
patients with aortoenteric fistula. We prefer EAB and IGR 
in treating these patients. 
Dr. Averill Mansfield (London, United Kingdom). 
My colleague, John Wolfe, and I deal with this problem in 
an almost identical way and strongly support he approach 
rather than the increasingly popular conservative manage- 
ment. In our own series, there are a number of patients who 
have undergone previous conservative measures and all of 
them had spent a significantly greater number of days in the 
hospital and had a larger number of procedures before the 
definitive xcision. 
The question is how to resolve the dilemma about 
which of these two modes of management would be best 
in an individual. Do you believe it would be feasible to do 
a randomized trial of these two alternative management 
regimens? 
Dr. Kuestner. You asked if there is any way to create 
a prospective study to support our recommendation f 
EAB and IGR. Our  response is that the incidence of 
aortoenteric fistula is extremely low, that is, 0.36% 
to 1.6% of patients who undergo aortic prosthetic graft- 
ing, so collecting a large series is quite difficult. To 
perform a prospective study, a multicenter t ial would be 
needed. 
